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Abstract
Background: Sumoylation has emerged as an important posttranslational regulatory mechanism
for transcription factors and cofactors. Sumoylation of many transcription factors represses their
transcriptional activities. The myocyte enhancer factor 2 (MEF2) family of transcription factors
plays an important role in regulating gene expression during myogenesis and has been recently
shown to be sumoylated.
Results: Consistent with earlier reports, we show that sumoylation of MEF2C at K391 inhibits its
transcriptional activity. Sumoylation of MEF2C does not block its DNA-binding activity. A small C-
terminal fragment of MEF2C containing K391, referred to as delta-N2-MEF2C, is efficiently
sumoylated and, when targeted to DNA, represses transcription at neighbouring promoters.
Because delta-N2-MEF2C lacks the binding site for class II histone deacetylases (HDACs), this
result suggests that sumoylation of MEF2C may help to recruit transcriptional repressors other
than these HDACs. Intriguingly, we show that phosphorylation of S396 in MEF2C, a residue in close
proximity to the major sumoylation site (K391) and known to be phosphorylated in vivo, enhances
sumoylation of delta- N2-MEF2C in vitro. The S396A mutation reduces sumoylation of MEF2C in
vivo and enhances the transcription activity of MEF2C in reporter assays.
Conclusion: We propose that phosphorylation of MEF2C at S396 facilitates its sumoylation at
K391, which in turn recruits yet unidentified co-repressors to inhibit transcription. Our studies
further suggest that sumoylation motifs containing a phosphorylated serine or an acidic residue at
the +5 position might be more efficiently sumoylated.
Background
Transcription factors and cofactors orchestrate complex
yet precise programs of gene expression that are critical for
cell proliferation and differentiation during development.
The myocyte enhancer factor 2 (MEF2) family of tran-
scription factors regulates diverse cellular processes in a
wide range of cell types [1]. In muscle cells, the MEF2 fam-
ily of proteins binds to the promoters of many muscle-
specific genes and activates their transcription during
muscle differentiation [2]. There are four MEF2 proteins,
MEF2A, -B, -C, and -D, in vertebrates [1]. They contain a
MADS box and an adjacent MEF2 motif at their N-termini
that mediate DNA binding, homo- and hetero-dimeriza-
tion, and cofactor binding [1,3,4]. They also contain a
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transcriptional activation domain at their C-termini [2].
Homozygous mef2c null mice are embryonic lethal due to
defective cardiac myogenesis and morphogenesis [5,6]
whereas mef2a null mice die suddenly shortly after birth
due to defects in post-natal cardiomyocytes [7]. Therefore,
among other functions, MEF2 proteins play essential and
distinct roles during cardiac muscle development. In addi-
tion, mutations of human MEF2A have been implicated
in the pathogenesis of a familial coronary artery disease
[8].
The functions of MEF2 proteins are regulated by their
direct physical interactions with a large collection of
cofactors, including thyroid hormone receptor, MyoD,
NFAT, GATA, p300, GRIP1, histone deacetylases
(HDACs), and MITR [9-16]. The class II HDACs (HDAC4,
-5, -7, and -9) contain a characteristic MEF2-interacting
domain at their N-termini [3,4] and an HDAC catalytic
domain at their C-termini. They bind to the MADS/MEF2
domain of MEF2 proteins and repress their transcriptional
activity [13]. In addition to cofactor binding, MEF2 pro-
teins are also regulated by multiple phosphorylation
events [1]. Several kinases, including p38 MAP kinase,
ERK5, and CDK5, can phosphorylate MEF2 proteins and
regulate their transcriptional activity [17-19]. Phosphor-
ylation of MEF2 by p38 occurs in the transcriptional acti-
vation domain of MEF2 and stimulates its transcriptional
activity [19]. Recently, it has been shown that an alterna-
tive splicing event within the last coding exon of MEF2C
leads to the formation of two MEF2C isoforms, only one
of which contains a 32-residue domain called γ [20]. The
MEF2C-(γ-) isoform has higher transcriptional activity
than does MEF2C-(γ+), and a Gal4-γ-domain fusion pro-
tein represses the basal level transcription of a promoter
with Gal4-binding sites [20]. Interestingly, Ser 396 within
the γ-domain is phosphorylated and the S396A mutation
diminishes the transcriptional repression activity of the γ-
domain [20]. These results suggest that the γ-domain
might recruit transcriptional repressors in a phosphoryla-
tion-dependent manner. Because a motif similar to the γ-
domain is constitutively present in MEF2A, -B, and -D,
phosphorylation within this motif might negatively regu-
late the transcriptional activities of other MEF2 proteins.
Small Ubiquitin-like Modifier (SUMO) is structurally
related to ubiquitin and is covalently conjugated to lysine
residues of target proteins through an amide bond
[21,22]. There are at least three mammalian SUMO pro-
teins, SUMO1, -2, and -3. SUMO2 and -3 share greater
than 90% sequence identity while both are about 50%
identical to SUMO1 [21,22]. Sumoylation is catalyzed by
a set of enzymes, including E1-activating enzyme (AOS1/
UBA2), E2-conjugating enzyme (UBC9), and E3 ligases
[21,22]. Three types of SUMO E3 ligases, RanBP2, the
PIAS proteins, and Pc2, have been identified [21,22]. They
exhibit different subcellular localization patterns and
might enhance sumoylation of specific subsets of SUMO
substrates in vivo [23-26]. Like ubiquitination, sumoyla-
tion is a dynamic process and is actively reversed by
SUMO-specific proteases, including SENP1, -2, -3 and -6
[21,22]. Unlike ubiquitination, sumoylation does not
generally lead to degradation of target proteins [21,22].
Instead, sumoylation regulates the functions of substrate
proteins in multiple ways, including controlling their sub-
cellular localization, affecting their interactions with other
proteins, or increasing their stability through antagoniz-
ing ubiquitination [21,22]. Many transcriptional factors
and cofactors are sumoylated and, in most cases,
sumoylation inhibits their transcriptional activity
[21,22,27-35]. Sumoylation of Elk-1 and p300 enhances
their binding to HDAC2 and -6, respectively, suggesting
that sumoylation might repress transcription through
recruitment of transcriptional repressors, such as HDACs
[36,37]. However, it remains to be established whether
HDAC recruitment is a general mechanism for transcrip-
tional repression by sumoylation.
We have previously identified human MEF2 proteins as
SUMO1 substrates using an in vitro expression cloning
(IVEC) strategy [38]. In addition, MEF2C and MEF2D
have very recently been shown to be modified by SUMO2
and SUMO3 [39]. Sumoylation of MEF2 is enhanced by
class IIa HDACs and by SIRT1-mediated deacetylation of
the lysine acceptor for SUMO [39,40]. Here we further
confirm the sumoylation of MEF2C in vivo and identify
K391 as the major sumoylation site of MEF2C. As com-
pared to the wild-type MEF2C, the MEF2C-K391R mutant
has higher transcriptional activity in reporter assays, and
is more efficient in promoting the conversion of 10T1/2
cells into myocytes when co-expressed with MyoD. These
findings suggest that sumoylation of MEF2C inhibits its
transcriptional activity. Sumoylation of MEF2C does not
appear to affect its binding to DNA, its interactions with
HDACs, or its phosphorylation by p38. Interestingly,
K391 is located in the γ-domain and in close proximity to
S396, which can be phosphorylated by unknown
kinase(s) [20]. When fused to Gal4, a C-terminal fragment
of MEF2C containing the γ-domain is sufficient to repress
transcription of a promoter that contained Gal4-binding
sites. Mutations of either K391 or S396 abolish the tran-
scriptional repression activity of the Gal4-MEF2C fusion
protein. Moreover, phosphorylation of S396 enhances the
sumoylation of the C-terminal domain of MEF2C in vitro.
The S396A mutation reduces the degree of MEF2C
sumoylation in vivo. We propose that phosphorylation of
S396 facilitates the sumoylation of MEF2C, which in turn
recruits yet unidentified transcriptional repressors to
inhibit transcription.BMC Biochemistry 2006, 7:5 http://www.biomedcentral.com/1471-2091/7/5
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Results
MEF2C is sumoylated at K391 in vivo
We and Gregoire et al. had previously shown that the
MEF2 family of transcription factors was efficiently
sumoylated [38,39]. As shown in Figure 1A, MEF2C was
modified in the presence of E1 (AOS1/UBA2), E2
(UBC9), and SUMO1. His6-SUMO1 resulted in a further
shift in gel mobility as compared to untagged SUMO1
(Figure 1A). The yeast SUMO isopeptidase, Ulp1, effi-
ciently reversed this modification (Figure 1A). MEF2C
contains a sumoylation motif, ΦKXE (Φ, hydrophobic res-
idues; X, any residues) [41,42] in the γ-domain of MEF2C
[20] that is highly conserved among other members of the
MEF2 family (Figure 1B). We mutated the lysine residue
in this motif (K391) to arginine and observed the MEF2C-
K391R is no longer sumoylated in vitro (Figure 1C). We
then examined the sumoylation of MEF2C in HeLa and
NIH3T3 cells (Figure 1D and data not shown). A signifi-
MEF2 proteins are sumoylated Figure 1
MEF2 proteins are sumoylated. (A) The 35S-labeled MEF2C protein obtained through in vitro transcription and translation 
was incubated with SUMO reaction mixtures and analyzed by SDS-PAGE followed by autoradiography. (B) Sequence align-
ment of the MEF2 family of proteins. The lysine residue of a sumoylation consensus motif and a serine residue that is phospho-
rylated are shown in bold. (C) The 35S-labeled wild-type (WT) and K391R mutant of MEF2C were incubated with SUMO 
reaction mixtures and analyzed by SDS-PAGE followed by autoradiography. (D) HeLa cells were transfected with the indicated 
plasmids. Myc-MEF2C was immunoprecipitated with anti-Myc. Cell lysates and Myc IP were resolved by SDS-PAGE and blotted 
with anti-Myc or anti-GFP. (E) HeLa cells were transfected with the indicated plasmids. Cell lysates were resolved by SDS-
PAGE and blotted with anti-Myc. (F) HeLa cells were transfected with the indicated plasmids. Cell lysates were resolved by 
SDS-PAGE and blotted with anti-Myc.BMC Biochemistry 2006, 7:5 http://www.biomedcentral.com/1471-2091/7/5
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cant fraction of Myc-MEF2C, but not Myc-MEF2C-K391R,
was converted to a slow-migrating species when it was co-
expressed with GFP-SUMO1 (Figure 1D, top panel). We
then immunoprecipitated Myc-MEF2C and blotted the
immunoprecipitates with anti-GFP. The slower migrating
band contained GFP-SUMO1 (Figure 1D, middle panel).
Furthermore, we observed that overexpression of SUMO
isopeptidase, SENP2, or a dominant-negative mutant of
UBC9 (DN-UBC9) greatly reduced the intensity of this
slow-migrating band of Myc-MEF2C (Figure 1E). Co-
expression of the PIAS family of E3 ligases, PIASxβ,
enhanced the sumoylation of Myc-MEF2C-WT (Figure
Sumoylation-deficient mutant of MEF2C promotes myogenic conversion more efficiently Figure 2
Sumoylation-deficient mutant of MEF2C promotes myogenic conversion more efficiently. (A) MEF2C-WT- or 
MEF2C-K391R-expressing plasmids were co-transfected with MEF2×3-luciferase reporter, pRL-tk reporter, and GFP-SUMO1 
or empty vector plasmids into HeLa cells. Firefly luciferase activities were measured and normalized for transfection efficiency 
by using Renilla luciferase activities. (B) MEF2×3-luciferase reporter, pRL-tkreporter, and MKK6-DD plasmids were co-trans-
fected with GFP-SUMO1, SENP2, or empty vector plasmids into C2C12 cells. The cells were cultured in differentiation 
medium for 2 days. Firefly luciferase activities were measured and normalized for transfection efficiency by using Renilla luci-
ferase activities. (C) Vector, MEF2C-WT-, MEF2C-K391R-, or GFP-SUMO1-expressing constructs were co-transfected with 
Myc-MyoD into 10T1/2 cells. The cells were cultured in differentiation medium for 5 days, fixed, and stained with DAPI (blue) 
and an anti-myosin heavy chain (MHC) monoclonal antibody (red). (D) MHC-positive cells were scored by random selection 
of 20 optical fields of cells in (C). The results of two independent experiments were averaged with the standard deviation indi-
cated. P value was calculated using student t test. Cell lysates were resolved by SDS-PAGE and blotted with anti-MEF2C or 
Myc.BMC Biochemistry 2006, 7:5 http://www.biomedcentral.com/1471-2091/7/5
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1F), but not that of Myc-MEF2C-K391R. These data indi-
cate that MEF2C is sumoylated in vivo and K391 is the
major sumoylation site of MEF2C in living cells.
Sumoylation of MEF2C reduces its transcriptional activity
We next used a luciferase reporter assay to examine
whether sumoylation of MEF2C regulates its transcrip-
tional activity. The luciferase reporter construct contained
three tandem copies of MEF2-binding sites at the pro-
moter region. The transcriptional activity of MEF2C-
K391R (the sumoylation-deficient mutant) was about
two-fold higher than that of the wild-type MEF2C (Figure
2A), suggesting that sumoylation of MEF2C inhibits its
transcription activity. Overexpression of GFP-SUMO1
downregulates the transcription activity of both MEF2C-
WT and K391R (Figure 2A). Because overexpression of
GFP-SUMO1 caused a global increase in the sumoylation
of many cellular proteins (data not shown), inhibition of
MEF2C-K391R by GFP-SUMO1 overexpression was most
likely due to the enhanced sumoylation of other MEF2C
regulatory proteins under these conditions. However, we
cannot completely rule out the possibility that MEF2C is
sumoylated at a second site, the sumoylation of which is
below the detection limit of our assay.
We next examined whether sumoylation affected the acti-
vation of endogenous MEF2C by the p38MAPK pathway.
To do so, we transfected a constitutively active mutant of
MKK6 (an upstream activator of p38MAPK) into C2C12
cell lines, together with GFP-SUMO1 or SENP2. Overex-
pression of GFP-SUMO1 reduced the transcriptional
activity of MEF2C whereas overexpression of SENP2
enhanced the activity of MEF2C in the presence of consti-
tutively active MKK6 (Figure 2B). These results are consist-
ent with the notion that sumoylation of MEF2C inhibits
the transcription activity of the endogenous MEF2C stim-
ulated by the p38MAPK pathway. However, it is entirely
possible that alteration of the sumoylation levels of other
MEF2C regulatory proteins is responsible for the observed
effects of GFP-SUMO and SENP2.
Embryonic fibroblast cells can be converted into myob-
lasts upon overexpression of MyoD and MEF2 [13,43].
We tested whether MEF2C-K391R was more active than
MEF2C-WT in collaborating with MyoD to promote the
conversion of 10T1/2 cells into myoblasts. We transfected
MyoD- and MEF2C-expressing plasmids into 10T1/2 cells
and cultured these cells in low-serum media to induce the
differentiation of the converted myoblasts into myotubes.
On the fifth day after the induction of differentiation, the
cells were fixed and stained with an antibody against
myosin heavy chain (MHC), a well-established myogenic
differentiation marker (Figure 2C and 2D). Co-expression
of MEF2C-WT together with MyoD slightly increased the
number of myotubes, as compared to the expression of
Sumoylation of MEF2C inhibits its transcriptional activity Figure 3
Sumoylation of MEF2C inhibits its transcriptional 
activity. (A) Gal4, Gal4-MEF2C-WT, or Gal4-MEF2C-
K391R construct was co-transfected with GAL4×5-luciferase 
reporter and pRL-tk reporter into HeLa cells. Firefly luci-
ferase activities were measured and normalized for transfec-
tion efficiency by using Renilla luciferase activities. (B) Gal4-
MEF2C-WT or Gal4-MEF2C-K391R construct was co-trans-
fected with GAL4×5-luciferase reporter, pRL-tk reporter, and 
SENP2, DN-UBC9-Flag, or vector construct into HeLa cells. 
Firefly luciferase activities were measured and normalized for 
transfection efficiency by using Renilla luciferase activities and 
then divided by the luciferase activities of Gal4-MEF2C-WT 
or Gal4-MEF2C-K391R, respectively, to show the fold differ-
ences. (C) Gal4, Gal4-MEF2C-WT, or Gal4-MEF2C-K391R 
construct was co-transfected with LexA×8-GAL4×5-luciferase 
reporter, pRL-tk reporter, and LexA-VP16 construct into 
HeLa cells. Firefly luciferase activities were measured and 
normalized for transfection efficiency by using Renilla luci-
ferase activities.BMC Biochemistry 2006, 7:5 http://www.biomedcentral.com/1471-2091/7/5
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MyoD alone (Figure 2D). Co-expression of MEF2C-
K391R with MyoD increased the myoblast conversion rate
by two-fold (P < 0.05) (Figure 2D). The expression levels
of MEF2C-WT and MEF2C-K391R were similar (Figure
2D, left panel). These results suggest that sumoylation of
MEF2C down-regulates its transcriptional activity during
muscle differentiation.
Sumoylation of MEF2C recruits transcriptional repressors 
other than Class II HDACs
We next sought to determine the mechanism by which
sumoylation inhibits the transcriptional activity of
MEF2C. We first tested whether sumoylation reduced the
DNA-binding activity of MEF2C using the chromatin
immunoprecipitation (ChIP) assay. Similar amounts of
MEF2C-WT or MEF2C-K391R bound to the desmin pro-
moter in a reporter plasmid [see Additional file 1], sug-
gesting that sumoylation does not affect the DNA-binding
activity of MEF2C. We next tested whether sumoylation of
MEF2C increases its binding to HDACs, such as HDAC4
and HDAC5. MEF2C-WT and MEF2C-K391R bound
equally well to HDAC4 or HDAC5 [see Additional file 1],
suggesting that sumoylation of MEF2C does not recruit
class II HDACs.
A small C-terminal fragment of MEF2C is sufficient to repress transcription in a sumoylation-dependent manner Figure 4
A small C-terminal fragment of MEF2C is sufficient to repress transcription in a sumoylation-dependent man-
ner. (A) Schematic drawing of the functional domains and two C-terminal fragments of MEF2C. (B) Gal4-MEF2C-WT, Gal4-
MEF2C-K391R, Gal4-MEF2C-∆N1, or Gal4-MEF2C-∆N1-K391R construct was co-transfected with GAL4×5-luciferase 
reporter and pRL-tk reporter constructs into HeLa cells. Firefly luciferase activities were measured and normalized for trans-
fection efficiency by using Renilla luciferase activities. (C) Gal4, Gal4-MEF2C-∆N2, or Gal4-MEF2C-∆N2-K391R construct was 
cotransfected with LexA×8-GAL4×5-luciferase reporter, pRL-tk reporter, and LexA-VP16 constructs into HeLa cells. Firefly 
luciferase activities were measured and normalized for transfection efficiency by using Renilla luciferase activities. (D) HeLa 
cells were transfected with the indicated plasmids. The total cell lysates were resolved by SDS-PAGE and blotted with anti-
MEF2C. The asterisk indicates the endogenous MEF2 proteins.BMC Biochemistry 2006, 7:5 http://www.biomedcentral.com/1471-2091/7/5
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Since sumoylation inhibits the activation of the endog-
enous MEF2C by the p38MAPK pathway (Figure 2B), we
thus tested whether sumoylation and p38 phosphoryla-
tion of MEF2C are antagonistic. However, we observed
that sumoylation does not affect the binding affinity of
MEF2C toward p38 or phosphorylation of MEF2C by p38
[see Additional file 1]. Likewise, phosphorylation of
MEF2C by p38 does not appear to block sumoylation of
MEF2C in vivo [see Additional file 1]. Thus, there is no sig-
nificant interplay between sumoylation and p38 phos-
phorylation of MEF2C.
To further study how sumoylation reduced the transcrip-
tional activity of MEF2C, we measured the transcriptional
activity of Gal4 fusion proteins of MEF2C and MEF2C-
K391R, using luciferase reporter assays with a reporter
construct that contained Gal4-binding sites. As compared
to Gal4-MEF2C-WT, Gal4-MEF2C-K391R was much more
active in stimulating transcription (Figure 3A). Overex-
pression of DN-UBC9 or SENP2 greatly increased the
transcriptional activity of Gal4-MEF2C-WT, but not Gal4-
MEF2C-K391R (Figure 3B). These data indicate that
sumoylation also inhibits the transcriptional activity of
MEF2C at a promoter that does not contain MEF2C-bind-
ing sites, consistent with the fact that sumoylation does
not affect the DNA-binding activity of MEF2C.
We next performed luciferase reporter assays with a
reporter construct that contained both Gal4- and LexA-
binding sites. LexA-VP16 (a fusion protein of the LexA
DNA-binding domain and the VP16 transactivation
domain) dramatically stimulated the transcription of this
reporter gene (Figure 3C). Co-expression of Gal4-MEF2C-
WT, but not Gal4-MEF2C-K391R, greatly reduced the
transcriptional activity of LexA-VP16 (Figure 3C). This
suggests that Gal4-MEF2C might recruit transcriptional
repressors to this artificial promoter in a manner that is
dependent on its sumoylation.
Since sumoylation of MEF2C does not appear to affect its
binding to HDAC4 and HDAC5, recruitment of these
HDACs is unlikely to be responsible for the transcrip-
tional repression activity of Gal4-MEF2C. To further test
this notion, we constructed Gal4-fusion proteins of two
C-terminal MEF2C fragments, termed ∆N1 and ∆N2, and
their corresponding K391R mutants, and tested their abil-
ities to stimulate/repress transcription in reporter assays
(Figure 4A). MEF2C-∆N1 lacked the N-terminal MADS/
MEF2 domain that is required for HDAC-binding whereas
∆N2 lacked both the MADS/MEF2 domain and the trans-
activation domain (Figure 4A). As shown in Figure 4B,
Gal4-MEF2C-∆N1-K391R was much more active in pro-
moting transcription of the reporter gene that contained
Phosphorylation of MEF2C at S396 and sumoylation of MEF2C at K391 repress transcription through the same pathway Figure 5
Phosphorylation of MEF2C at S396 and sumoylation of MEF2C at K391 repress transcription through the same 
pathway. (A) Three possible models with respect to the relationship between phosphorylation and sumoylation of MEF2C. 
(B) GAL4×5-luciferase reporter and pRL-tk reporter constructs were co-transfected with various Gal4-MEF2C constructs into 
HeLa cells. Firefly luciferase activities were measured and normalized for transfection efficiency by using Renilla luciferase activ-
ities. (C) LexA×8-GAL4×5-luciferase reporter, pRL-tk reporter, and LexA-VP16 constructs were cotransfected with various 
Gal4-MEF2C constructs into HeLa cells. Firefly luciferase activities were measured and normalized for transfection efficiency by 
using Renilla luciferase activities.BMC Biochemistry 2006, 7:5 http://www.biomedcentral.com/1471-2091/7/5
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Gal4-binding sites at its promoter, suggesting that
MEF2C-∆N1 retained the ability to be regulated by
SUMO. Furthermore, Gal4-MEF2C-∆N2, but not Gal4-
MEF2C-∆N2-K391R repressed the activity of LexA-VP16
to stimulate transcription of the reporter gene whose pro-
moter contained both Gal4- and LexA-binding sites (Fig-
ure 4C). Expectedly, both GAL4-MEF2C-∆N1 and Gal4-
MEF2C-∆N2 were sumoylated in HeLa cells when co-
expressed with GFP-SUMO1 (Figure 4D). Since MEF2C-
∆N1 and MEF2C-∆N2 lack the HDAC-binding domain of
MEF2C, these data suggest that sumoylation of MEF2C
might mediate the recruitment of transcriptional repres-
sors other than class II HDACs to repress the transcrip-
tional activities of Gal4-MEF2C or LexA-VP16. In
addition, MEF2C-∆N2 lacks the p38 phosphorylation
sites and yet retains the ability to be regulated by sumoyla-
MEF2C-S396A is less efficiently sumoylated in vitro and in vivo Figure 6
MEF2C-S396A is less efficiently sumoylated in vitro and in vivo. (A) The recombinant GST-MEF2C-∆N2-WT or GST-
MEF2C-∆N2-S396A proteins were subjected to CDK1 kinase assays and analyzed by SDS-PAGE followed by autoradiography. 
(B) 0.75 µg of GST-MEF2C-∆N2-WT, S396A, or S396E proteins were incubated with 1 µg of E1, 0.5 µg of E2, and 1.25 µg of 
His6-SUMO1 for the indicated time and stopped by SDS-PAGE sample buffer. The samples were resolved by SDS-PAGE and 
blotted with anti-MEF2C. (C) 0.3 µg of GST-MEF2C-∆N2-WT, S396A, or S396E proteins were subjected to CDK1 kinase 
assays and then incubated with 0.2 µg of E1, 0.1 µg of E2, and 0.3 µg of His6-SUMO1 for 15 min and stopped by SDS-PAGE 
sample buffer. The samples were resolved by SDS-PAGE and blotted with anti-MEF2C. (D) 10T1/2 cells were transfected with 
the indicated plasmids. Cell lysates were resolved by SDS-PAGE and blotted with anti-MEF2C. (E) Sequence alignment of the 
sumoylation sites of several SUMO substrates. Conserved amino acids were shown in bold.BMC Biochemistry 2006, 7:5 http://www.biomedcentral.com/1471-2091/7/5
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tion. This is consistent with the notion that sumoylation
does not repress the transcriptional activity of MEF2C
through reducing p38 phosphorylation of MEF2C.
Phosphorylation of S396 facilitates sumoylation of MEF2C
Recently, S396, a conserved serine residue in the C-termi-
nal γ-domain of MEF2C, has been shown to be phospho-
rylated [20]. MEF2C-S396A or a MEF2C splicing variant
that lacks the γ-domain is much more active in transcrip-
tional reporter assays [20]. Moreover, γ-domain alone
when fused to Gal4 can repress the basal transcriptional
activity of Gal4, and this repression is diminished by the
S396A mutation [20]. These findings indicate that phos-
phorylation of S396 inhibits the transcriptional activity of
MEF2 proteins by recruiting transcriptional repressors.
Interestingly, the major sumoylation site of MEF2C, K391,
is located in the vicinity of S396 (Figure 1B and 5A).
We therefore tested whether phosphorylation of S396
affected the sumoylation of MEF2C. We envisioned three
possible scenarios (a, b, and c) with respect to the rela-
tionship between phosphorylation of S396 and sumoyla-
tion at K391 (Figure 5A). In model a, phosphorylation
and sumoylation are independent of each other. In this
case, mutations of K391R and S396A are expected to have
additive or synergistic effects in reporter assays. In models
b and c, sumoylation of K391 is dependent on phospho-
rylation of S396, or vice versa. Gal4-MEF2C-K391R acti-
vated the transcription of a reporter gene that contained
Gal4-binding sites much more efficiently than did Gal4-
MEF2C-WT (Figure 5B). The Gal4-MEF2C-K391R,S396A
double mutant did not exhibit higher transcriptional
activity than did Gal4-MEF2C-K391R (Figure 5B). Simi-
larly, both Gal4-MEF2C-∆N2-K391R and Gal4-MEF2C-
∆N2-K391R,S396A completely lost the ability to repress
the transcriptional activity of LexA-VP16 toward a reporter
gene that contained both Gal4- and LexA-binding sites
(Figure 5C). These data are consistent with the notion that
phosphorylation of S396 and sumoylation of K391 act
through the same pathway to repress transcription, and
model  a  is unlikely to be correct. Furthermore, Gal4-
MEF2C-S396A was less active in promoting transcription
than Gal4-MEF2C-K391R (Figure 5B). Similarly, Gal4-
MEF2C-∆N2-S396A still retained partial activity in
repressing the transcriptional activity of LexA-VP16 (Fig-
ure 5C). Although MEF2C-S396E (a phospho-mimicking
mutant) was slightly more active than the MEF2C-WT for
unknown reasons (see Discussion), it was much less
active than the S396A mutant (Figure 5B and 5C). While
we cannot rule out model c, our data are more consistent
with model b, in that sumoylation of MEF2C is the key
event in inhibiting its transcriptional activity and phos-
phorylation of S396 might facilitate the sumoylation of
MEF2C at K391.
To directly test this hypothesis, we expressed and purified
GST-MEF2C-∆N2 and the corresponding S396A and
S396E mutants from E. coli and examined their phospho-
rylation by Cdk1/Cyclin B1. CDK1/Cyclin B1 phosphor-
ylated GST-MEF2C-∆N2-WT to a greater extent than the
MEF2C-∆N2-S396A mutant (Figure 6A), suggesting that
Cdk1/Cyclin B1 can phosphorylate MEF2C at S396. We
then examined the sumoylation of recombinant GST-
MEF2C-∆N2-WT, S396A, and S396E proteins in vitro. As
shown in Figure 6B, at high concentrations of SUMO reac-
tion components and these substrate proteins, all three
GST-MEF2C-∆N2 proteins were efficiently sumoylated in
vitro. The S396E mutant was slightly more efficiently
sumoylated (Figure 6B). We next tested whether phospho-
rylation of MEF2C-∆N2 by Cdk1 affected its sumoylation.
Because sumoylation of the S396A mutant was already
very efficiently sumoylated at high concentrations of
SUMO enzymes, we performed the SUMO reactions with
much lower concentrations of SUMO reaction compo-
nents and substrates. Under these conditions, addition of
Cdk1/Cyclin B1 enhanced the sumoylation of GST-
MEF2C-∆N2-WT, but not the S396A mutant (Figure 6C).
Furthermore, the S396E mutant was more efficiently
sumoylated than WT or S396A proteins in the absence of
Cdk1/Cyclin B1, and was not further enhanced by Cdk1/
Cyclin B1 (Figure 6C). These results suggest that phospho-
rylation of S396 facilitates the sumoylation of MEF2C-
∆N2 in vitro.
We note that the S396A mutation and the K391R/S396A
double mutation in the context of the full-length MEF2C
appeared to abrogate the transcriptional repression activ-
ity of Gal4-MEF2C to similar extents (Fig. 5B). On the
other hand, the K391R/S396A double mutation in the
context of ∆N2-MEF2C had a significantly larger effect
than the S396A mutation in diminishing the transcrip-
tional repression activity of Gal4-∆N2-MEF2C (Fig. 5C).
The underlying reasons for this difference is unclear at
present. An intriguing possibility is that, as compared to
the full-length MEF2C, sumoylation of ∆N2-MEF2C
might be less dependent on prior phosphorylation at
S396. Indeed, at later timepoints, ∆N2-MEF2C-S396A was
as efficiently sumoylated as ∆N2-MEF2C in vitro (Fig. 6B).
Unfortunately, the full-length MEF2C did not express well
in bacteria, which prohibited us from testing its sumoyla-
tion in vitro.
We next compared the sumoylation of MEF2C-WT,
MEF2C-S396A, and MEF2C-S396E in 10T1/2 cells in the
presence of GFP-SUMO1 overexpression (Figure 6D).
Consistent with the in vitro sumoylation assay, MEF2C-
S396A was again less efficiently sumoylated than MEF2C-
WT and MEF2C-S396E (Figure 6D). Therefore, these
results suggest that sumoylation of MEF2C at K391 is
facilitated by phosphorylation of S396 in vivo.BMC Biochemistry 2006, 7:5 http://www.biomedcentral.com/1471-2091/7/5
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Discussion
Many transcription factors and cofactors can be covalently
modified by SUMO [21,22,38]. Sumoylation of these fac-
tors generally leads to transcriptional repression.
Sumoylation of Elk-1 and p300 facilitates the recruitment
of HDAC2, and -6, respectively, suggesting that sumoyla-
tion might repress transcription through the recruitment
of HDACs to promoters [36,37]. In addition to HDACs,
Daxx was shown to be another co-repressor that contrib-
utes to SUMO-mediated repression of transcription
[44,45].
In this study, we show that MEF2C is sumoylated in vitro
and in vivo, and sumoylation inhibits its transcriptional
activity. Sumoylation of MEF2C does not appear to affect
its DNA-binding, HDAC-recruitment, nuclear localization
[38], stability (data not shown), or p38 phosphorylation,
suggesting that sumoylation does not repress the tran-
scriptional activity of MEF2C through these mechanisms.
Moreover, when fused to Gal4, MEF2C-∆N2 that cannot
bind to class II HDACs and other transcriptional repres-
sors, including cabin1 [46] and MITR [16], is sufficient to
repress the ability of LexA-VP16 to activate transcription
from a promoter containing both Gal4- and LexA-binding
sites. The K391R mutation abolishes the transcriptional
repression activity of Gal4-MEF2C-∆N2, suggesting that
sumoylation of MEF2C-∆N2 recruits transcriptional
repressors other than class II HDACs. Class I HDACs does
not seem to be the repressor recruited after sumoylation
since overexpression of class I HDACs failed to repress the
transcriptional activity of MEF2C in reporter assays (data
not shown). Therefore, sumoylation of MEF2C appears to
repress its transcriptional activity through a novel mecha-
nism.
Regulation of the transcriptional activity of MEF2
Transcription activity of myogenic bHLH and MEF2 pro-
teins is tightly regulated during muscle differentiation.
Multiple pathways exist to ensure the repression of these
transcription factors in dividing myoblasts [47-49]. For
example, Cdk4/Cyclin D represses the activity of MEF2
proteins through blocking their interactions with the
GRIP1 co-activator [14], although it is unclear whether
Cdk4/Cyclin D phosphorylates MEF2 proteins directly. In
addition, another cyclin-dependent kinase, Cdk5, phos-
phorylates MEF2 proteins and inhibits their transcrip-
tional activity in neurons [18].
Consistent with recent findings by Gregoire and Yang
[39], we observed that sumoylation-deficient MEF2C has
higher myogenic activity than wild-type (Figure 2B and
2C), suggesting that sumoylation might be another
important mechanism to actively repress the transcrip-
tional activity of MEF2 proteins in dividing myocytes. Sur-
prisingly, only a very small population of MEF2C is
modified by SUMO in C2C12 cells (data not shown). It is
unclear how sumoylation of this small population of
MEF2C effectively suppresses the activity of cellular
MEF2C. On the other hand, this appears to be a recurring
theme in the sumoylation of transcriptional factors. One
intriguing possibility is that transient sumoylation of
these transcriptional factors recruits transcriptional
repressors that covalently modify the chromatin at the
transcriptional loci, which in turn establishes a relatively
long-lived chromatin state that is not permissible for tran-
scription. Alternatively, a "molecular memory" model has
been proposed to explain this phenomenon. In this
model, a protein molecule that has experienced a
sumoylation/desumoylation cycle is proposed to be func-
tionally distinct from one that has never experienced
sumoylation [50].
Regulation of sumoylation of MEF2 by phosphorylation
We have shown that sumoylation of MEF2C appears to be
facilitated by phosphorlyation of S396, since S396A
mutant is not as efficiently sumoylated in vivo and in vitro
as compared to the wild-type MEF2C. Phosphorylation by
Cdk1/Cyclin B1 enhances the sumoylation of MEF2C-
∆N2, but not that of MEF2C-∆N2-S396A. Surprisingly,
though the phospho-mimicking MEF2C-∆N2-S396E
mutant was more efficiently sumoylated than the wild-
type in vitro, MEF2C-S396E was less efficiently sumoylated
than the wild-type in vivo. Consistently, MEF2C-S396E
was slightly more active than the wild-type in transcrip-
tional assays. The reason for this discrepancy is unclear at
present. One possibility is that phosphorylated and
sumoylated MEF2C is a better substrate for SUMO iso-
peptidases in vivo. Phosphorylation at S396 of the wild-
type MEF2C can be reversed by phosphatases, resulting in
longer half-life of sumoylated MEF2C. In contrast, the
S396E mutant would be refractory to the actions of phos-
phatases. Even though MEF2C-S396E can be more effi-
ciently sumoylated as compared to the wild-type, it might
be also more prone to desumoylation of SUMO isopepti-
dases, resulting to its lower steady state of sumoylation in
vivo.
The kinase that mediates the phosphorylation of S396 in
vivo is currently unknown. Because S396 is followed by a
proline, the S396 kinase is likely to belong to families of
proline-directed kinases, such as cyclin-dependent kinases
and MAP kinases. Though Cdk1/Cyclin B1 is capable of
phosphorylating MEF2C at S396 in vitro, we do not think
that it is the relevant kinase that phosphorylates MEF2C at
this site in vivo. Cdk5 was shown to phosphorylate MEF2D
at this site in neurons [18]. However, the activity of Cdk5
is strictly dependent on its p35/p39 cofactor that is exclu-
sively expressed in neurons [51]. Furthermore, we did not
observe in vitro phosphorylation of MEF2C-∆N2 by Cdk5
alone (data not shown). Thus, yet unidentified kinase(s)BMC Biochemistry 2006, 7:5 http://www.biomedcentral.com/1471-2091/7/5
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mediate phosphorylation of MEF2C at S396 and conse-
quently sumoylation of MEF2C at K391 during muscle
differentiation.
There are precedents for phosphorylation-dependent
sumoylation. Phosphorylation of HSF1 and PPARγ has
recently been shown to facilitate their sumoylation
[52,53]. Intriguingly, similar to MEF2C, the phosphoryla-
tion sites on HSF1 and PPARγ are both followed by a pro-
line (Figure 6E). In all three cases, the sumoylation and
phosphorylation sites are separated by four residues (Fig-
ure 6E). Phosphorylation at +5 position by a proline-
directed kinase is expected to introduce negative charges
at this position, which may enhance the binding affinity
between UBC9 and the sumoylation motif. An inspection
of the known sumoylation sites reveals that a sumoylation
site of c-Myb is also followed by an SP motif at the +5 and
+6 positions, suggesting that sumoylation of c-Myb at this
site might also be regulated by phosphorylation [31]. In
addition, several known sumoylation sites contain an
acidic residue (D or E) at the +5 position (Figure 6E).
These extended sumoylation consensus motifs that con-
tain acidic residues at +5 position might be more effi-
ciently sumoylated.
Conclusion
The MEF2 family of transcriptional factors regulates cell
proliferation, differentiation, and apoptosis of many cell
types. The activities of MEF2 proteins are themselves reg-
ulated by multiple mechanisms, including sumoylation.
We have discovered that phosphorylation of a serine resi-
due in the vicinity of the sumoylation site facilitates
sumoylation of MEF2C. This finding also allows us to
define extended sumoylation consensus motifs that con-
tain SP at +5/+6 positions or an acidic residue at +5 posi-
tion.
Methods
Cell culture and transfection
HeLa, 10T1/2, and C2C12 cells were grown in Growth
Medium (DMEM supplemented with 10% fetal bovine
serum, 100 units/ml penicillin, and 0.1 mg/ml streptomy-
cin). Differentiation of MyoD-transfected 10T1/2 cells
was induced by substituting Growth Medium with Differ-
entiation Medium (DMEM supplemented with 2% horse
serum, 100 units/ml penicillin, and 0.1 mg/ml streptomy-
cin). Cells were plated and transfected in 12-well plates
for promoter-luciferase assays, 6-well plates for immuno-
precipitations, 10-cm plates for chromatin immunopre-
cipitation, and 4-well chambered slides for indirect
immunofluorescence microscopy. Cells were transfected
using the Effectene (Qiagen) or the Lipofectamine 2000
Plus (Invitrogen) reagents according to manufacturer's
protocols.
Plasmids and promoter assays
The coding regions of human SUMO1 (1–97) and SENP2
were amplified from human fetal thymus cDNA library
(BD Biosciences) by PCR and cloned into pCS2 mamma-
lian expression vectors that contain N-terminal Myc, HA,
or GFP tags. PIASxβ was amplified from pGEX-PIASxβ
constructs provided by S. Muller and cloned into the
pCS2-HA vector. UBC9 was cloned into a pCS2 vector that
contains a C-terminal Flag tag. The pCDNA-MEF2C,
pCDNA-Flag-HDAC4, pCDNA-Flag-HDAC5, and
pCDNA-Myc-MyoD constructs were obtained from E.
Olson. The pCMV5-HA-p38 and pCMV5-MKK6-DD plas-
mids were gifts from M. Cobb. The dominant-negative
UBC9 mutant and various MEF2C mutants were con-
structed with the QuikChange site-directed mutagenesis
kit (Stratagene). The pET11c-hAOS1, pET28b-hUBA2,
and pET28b-hUBC9 vectors were gifts from C. Lima and
K. Orth.
Promoter assays were performed in triplicates with the
dual-luciferase reporter assay system (Promega) according
to manufacturer's protocols. Luciferase activity was meas-
ured with a Turner Designs luminometer and normalized
for transfection efficiency using the activity of Renilla luci-
ferase. The MEF2-responsive promoter activity assays were
performed with a pMEF2×3-Luc construct (provided by E.
Olson). The Gal4/LexA-promoter activity assay was per-
formed with a pL8G5-Luc plasmid with or without the
transfection of a pLexA-VP16 construct.
Immunofluorescence
10T1/2 fibroblast cells transfected with various plasmids
were fixed with 4% paraformaldehyde and permeablized
with 0.1% Triton-X100 in PBS. An antibody against
myosin heavy chain (MHC) was then added at 1:4 dilu-
tions. After washing, fluorescent secondary antibodies
(Molecular Probes) were added at 1:500 dilutions. The
cells were washed with PBS, counter-stained with DAPI,
and viewed using a 20× objective on a Zeiss Axiovert 200
M microscope. Images were acquired using the Intelligent
Imaging software and pseudo-colored in Adobe Pho-
toshop.
Immunoprecipitation and immunoblotting
Cells were lysed in 400 µl of lysis buffer (50 mM Tris-HCl
at pH 7.7, 150 mM KCl, 0.5% NP-40, 5 mM MgCl2, 1 mM
DTT, 0.5 µM okadaic acid, 10 mM N-ethylmaleimide,
supplemented with protease inhibitors; Sigma) for 30
min on ice. After brief sonication, insoluable materials
were pelleted by centrifugation at 15,800 × g for 30 min at
4°C. Myc-tagged MEF2C was immunoprecipitated using
0.4  µg of anti-Myc (9E10) monoclonal antibodies
(Roche). After incubation at 4°C for 1 hr, 20 µl of Affi-
prep protein A beads (Bio-Rad) was added to each lysate
and incubated for 1 hr. The beads were washed with lysisBMC Biochemistry 2006, 7:5 http://www.biomedcentral.com/1471-2091/7/5
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buffer and eluted by SDS sample buffer. Eluted proteins
were resolved by SDS-PAGE and blotted with anti-Myc
(Roche), anti-GFP, or M5-anti-Flag (Sigma) monoclonal
antibodies.
Sumoylation assays
Plasmids that encode appropriate proteins were in vitro
transcribed and translated (IVT) in reticulocyte lysate in
the presence of 35S-methionine and subjected to in vitro
sumoylation reactions, which contained 2 µl of IVT prod-
uct, 2 µg of AOS1-UBA2, 0.5 µg of UBC9, 1 µg of SUMO1,
and 1 µl of Energy Mix (150 mM phosphocreatine, 20 mM
ATP, 2 mM EGTA, 20 mM MgCl2, adjust pH to 7.7). Reac-
tions were adjusted to a final volume of 10 µl with the XB
buffer (10 mM HEPES, pH 7.7, 1 mM MgCl2, 0.1 mM
CaCl2, 100 mM KCl, and 50 mM sucrose). Control reac-
tions contained water and XB buffer. After 2 hr at 30°C,
reactions were stopped with 10 µl of 2× SDS sample
buffer, boiled, and subjected to SDS-PAGE followed by
autoradiography.
Protein binding, kinase, and chromatin 
immunoprecipitation assays
For in vitro protein binding assays, 4 µg of purified His6-
p38 was incubated with 5 µl of Ni2+-NTA beads in 50 µl of
Q-A buffer (20 mM Tris, pH 7.7, 100 mM KCl, 1 mM
MgCl2) for 1 hr at room temperature. Beads were then
incubated with 400 µl of blocking solution (25 mM Tris,
pH 8.0, 150 mM NaCl, 2.5 mM KCl, 0.05% Tween-20, 5%
dry milk) for 1 hr at RT. 20 µl of in vitro sumoylated
MEF2C was added and incubated for another 1 hr at RT.
Beads were washed two times with blocking solution
without dry milk, eluted in 1× SDS sample buffer, and
subjected to SDS-PAGE followed by autoradiography.
For p38 in vitro kinase assays, 0.4 µg of purified His6-p38
was added in 10 µl of 2× Kinase Buffer A (25 mM Tris-
HCl, pH 7.7, 100 mM KCl, 5 mM β-glycerophosphate, 10
mM NaF, 1 mM DTT, 0.1 mM Na3VO4, 10 mM MgCl2)
containing 200 µM ATP. 10 µl of in vitro sumoylated
MEF2C was then added and incubated for 30 min at
30°C. The reaction was stopped by the addition of 5 µl of
5× SDS sample buffer and subjected to SDS-PAGE fol-
lowed by autoradiography. For CDK1 in vitro kinase
assays, 0.3 µg of purified GST-MEF2C-∆N2 and 6 µl of
purified GST-CDK1/Cyclin B1 (0.2 mg/ml) was incubated
for 1 h at 30°C in 10 µl volume containing 1 µl of 10×
Kinase Buffer B (25 mM Tris, pH 7.7, 50 mM KCl, 10 mM
MgCl2, 1 mM DTT), 200 µM ATP, and 0.4 µCi of γ-32P-
ATP. For sumoylation assays, kinase reactions were per-
formed in the presence of cold ATP. 10 µl of SUMO mix
containing 0.1 µg of AOS1-UBA2, 0.05 µg of UBC9, 0.2 µg
of His6-SUMO1, and 1 µl of Energy Mix in XB buffer was
added to the kinase reaction mixture. The reaction was
further incubated for 15 min at 30°C and stopped by the
addition of 20 µl of 2× SDS sample buffer.
Chromatin immunoprecipitation (ChIP) assays were per-
formed with a ChIP assay kit (Upstate) according to the
manufacturer's protocol.
List of abbreviations
MEF2, myocyte enhancer factor 2; HDAC. histone
deacetylase; SUMO, small ubiquitin-like modifier; ChIP,
chromatin immunoprecipitation; GFP, green fluorescent
protein.
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